Cover Image


View/Hide Left Panel

Young, C. W.; Schneider, R.; Leyland-Jones, B.; Armstrong, D.; Tan, C. T.; Lopez, C.; Watanabe, K. A.; Fox, J. J.; Philips, F. S. 1983. Phase 1 evaluation of 2'fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpes virus infection. Cancer Research; 43: 5006.

Zarafonetis, C. J. D.; Riley, P. A.; Willis, P. W.; Power, L. H.; Werbelow, J.; Farhat, L.; Beckwith, W.; Marks, B. H. 1978. Clinically significant adverse effects in a Phase I testing program. Clinical Pharmacology and Therapeutics; 24(2): 127-132.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement